By Connor Hart
Rezolute received an orphan-drug designation from the Food and Drug Administration for its treatment of hypoglycemia, or low blood sugar, caused by a disease in which a tumor produces too much insulin.
The Redwood City, Calif., company said Tuesday the treatment, ersodetug, is expected to start a Phase 3 registrational trial in 2025.
Ersodetug aims to treat tumor hyperinsulinism, a rare disease caused by two distinct types of tumors, both of which lead to low blood sugar as a result of excessive activation of the insulin receptor.
"Tumor HI requires directed treatments for hypoglycemia to prevent serious adverse outcomes and improve patients' quality of life, as well as to enable patients to continue cancer treatments," said Chief Regulatory Officer Susan Stewart.
The FDA's orphan-drug designation encourages the development of treatments for rare diseases, offering benefits including seven years of market exclusivity protection and the potential qualification for expedited pathways to approval.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 03, 2024 08:40 ET (13:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。